Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
Daisuke Kamakura, Ryutaro Asano, Masahiro Yasunaga
Pharmaceuticals (2021) Vol. 14, Iss. 11, pp. 1172-1172
Open Access | Times Cited: 18

Showing 18 citing articles:

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Jurriaan Brouwer‐Visser, Nathalie Fiaschi, Raquel P. Deering, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008338-e008338
Open Access | Times Cited: 10
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy
Xiaojing Qin, Wenjing Ning, Han Liu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2361-2377
Open Access | Times Cited: 8
Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
Camila Ordóñez‐Reyes, Juan Esteban García-Robledo, Diego F. Chamorro, et al.
Pharmaceutics (2022) Vol. 14, Iss. 6, pp. 1243-1243
Open Access | Times Cited: 28
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
Xiaohan Guo, Yi Wu, Xue Ying, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Immunotherapeutic progress and application of bispecific antibody in cancer
Jingyue Kang, Tonglin Sun, Yan Zhang
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20
PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
Ning Shi, Yangyihua Zhou, Yujun Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20
Nonshrinkable Thermosensitive Hydrogels Combined with Bispecific Anti-PSMA/CD3 T-Cell Engager for Effective Against Tumors in Mice Model
Pu-Sheng Wei, Po-Yu Chou, Hong‐Yuan Hsu, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 3083-3111
Open Access
Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
Luigi Liguori, Giovanna Polcaro, Annunziata Nigro, et al.
Pharmaceutics (2022) Vol. 14, Iss. 11, pp. 2442-2442
Open Access | Times Cited: 16
Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy
Ha Gyeong Shin, Ha Rim Yang, Aerin Yoon, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5686-5686
Open Access | Times Cited: 14
Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy
Carlos Carrasco-Padilla, Alicia Hernaiz-Esteban, Luís Álvarez-Vallina, et al.
Pharmaceutics (2022) Vol. 15, Iss. 1, pp. 132-132
Open Access | Times Cited: 10
Mechanism-based pharmacokinetic and pharmacodynamic modeling for bispecific antibodies: challenges and opportunities
Jin Niu, Weirong Wang, Danièle Ouellet
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 10, pp. 977-990
Closed Access | Times Cited: 3
A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022
Kaikai Yu, Bin Liu, Haotian Yu, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 2
Resistance to Immunotherapy in Breast Cancer
Botle Precious Damane, Lorraine Tshegofatso Maebele, Malose Makgoka, et al.
(2024), pp. 83-103
Closed Access
Bispecific T-Cell Engagers (BiTEs) in Immunotherapy
Mohsen Sheykhhasan, Anita Silas La’ah, Amirhossein Ahmadieh-Yazdi, et al.
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 205-234
Closed Access
Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions
Aldo Caltavituro, Roberto Buonaiuto, Fabio Salomone, et al.
Critical Reviews in Oncology/Hematology (2024), pp. 104577-104577
Open Access
Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting
Minghan Qiu, Shan Wu, Xinrui Chen, et al.
Cancer Biology and Medicine (2022) Vol. 19, Iss. 8, pp. 1117-1120
Open Access | Times Cited: 2
Development of Next-Generation Antibody Therapeutics Using DDS and Molecular Imaging
Masahiro Yasunaga
Springer eBooks (2023), pp. 1-31
Closed Access
Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells
Kouki Kimura, Atsushi Kuwahara, Saori Suzuki, et al.
Oncology Reports (2023) Vol. 50, Iss. 6
Open Access
Page 1

Scroll to top